Truist Securities Reiterates CorMedix (CRMD) at Buy, Calls DefenCath NDA Resubmission a "Huge Relief"

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. FIX
9. TSCO
10. BE

Go back to Truist Securities Reiterates CorMedix (CRMD) at Buy, Calls DefenCath NDA Resubmission a "Huge Relief"

CorMedix (CRMD) Announces Resubmission of New Drug Application for DefenCath

February 28, 2022 8:34 AM EST

CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has resubmitted the New Drug Application (NDA) for DefenCath to address the Complete Response Letter (CRL) issued by the U.S. Food and Drug Administration (FDA) a year ago. In parallel, the Companys third-party... More